Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: J Clin Psychopharmacol. 2019 Mar-Apr;39(2):108–116. doi: 10.1097/JCP.0000000000001015

Figure 1. Participants with One or More Observed NPSAE in the Primary Endpoint by Diagnostic Group*.

Figure 1.

* Period for ascertainment of NPS AEs is during 12 weeks treatment and 30-day follow-up.